PMC:7105881 / 936-1617 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"52","span":{"begin":52,"end":57},"obj":"Species"},{"id":"53","span":{"begin":110,"end":119},"obj":"Species"},{"id":"54","span":{"begin":179,"end":186},"obj":"Species"},{"id":"55","span":{"begin":285,"end":293},"obj":"Species"},{"id":"56","span":{"begin":298,"end":306},"obj":"Species"},{"id":"57","span":{"begin":350,"end":356},"obj":"Species"},{"id":"58","span":{"begin":447,"end":452},"obj":"Species"},{"id":"59","span":{"begin":453,"end":457},"obj":"Species"},{"id":"60","span":{"begin":520,"end":528},"obj":"Species"},{"id":"61","span":{"begin":533,"end":541},"obj":"Species"},{"id":"62","span":{"begin":623,"end":628},"obj":"Species"},{"id":"63","span":{"begin":629,"end":633},"obj":"Species"},{"id":"72","span":{"begin":58,"end":68},"obj":"Disease"},{"id":"73","span":{"begin":271,"end":281},"obj":"Disease"}],"attributes":[{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:2697049"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:2697049"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:694009"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:1335626"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"Tax:9606"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"Tax:9606"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:11118"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:694009"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:1335626"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:9606"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:11118"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:D007239"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the b"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":426,"end":434},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the b"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":58,"end":68},"obj":"Disease"},{"id":"T9","span":{"begin":271,"end":281},"obj":"Disease"},{"id":"T10","span":{"begin":285,"end":293},"obj":"Disease"},{"id":"T11","span":{"begin":520,"end":528},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the b"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":52,"end":57},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T10","span":{"begin":221,"end":222},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T11","span":{"begin":321,"end":324},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T12","span":{"begin":350,"end":356},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T13","span":{"begin":447,"end":452},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T14","span":{"begin":623,"end":628},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the b"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":426,"end":434},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the b"}

{"project":"LitCovid-sentences","denotations":[{"id":"T8","span":{"begin":70,"end":211},"obj":"Sentence"},{"id":"T9","span":{"begin":212,"end":357},"obj":"Sentence"},{"id":"T10","span":{"begin":358,"end":634},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the b"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T25","span":{"begin":52,"end":57},"obj":"SP_6;NCBITaxon:9606"},{"id":"T26","span":{"begin":110,"end":119},"obj":"SP_7"},{"id":"T27","span":{"begin":285,"end":293},"obj":"SP_10"},{"id":"T28","span":{"begin":298,"end":306},"obj":"SP_9"},{"id":"T29","span":{"begin":350,"end":356},"obj":"NCBITaxon:9606"},{"id":"T30","span":{"begin":447,"end":452},"obj":"SP_6;NCBITaxon:9606"},{"id":"T31","span":{"begin":520,"end":528},"obj":"SP_10"},{"id":"T32","span":{"begin":533,"end":541},"obj":"SP_9"},{"id":"T33","span":{"begin":623,"end":628},"obj":"SP_6;NCBITaxon:9606"},{"id":"T95839","span":{"begin":52,"end":57},"obj":"SP_6;NCBITaxon:9606"},{"id":"T58242","span":{"begin":110,"end":119},"obj":"SP_7"},{"id":"T89984","span":{"begin":285,"end":293},"obj":"SP_10"},{"id":"T56264","span":{"begin":298,"end":306},"obj":"SP_9"},{"id":"T11552","span":{"begin":350,"end":356},"obj":"NCBITaxon:9606"},{"id":"T28582","span":{"begin":447,"end":452},"obj":"SP_6;NCBITaxon:9606"},{"id":"T48545","span":{"begin":520,"end":528},"obj":"SP_10"},{"id":"T62193","span":{"begin":533,"end":541},"obj":"SP_9"},{"id":"T56881","span":{"begin":623,"end":628},"obj":"SP_6;NCBITaxon:9606"}],"text":"transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the b"}